A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Clinical trial NCT06682793 · RECRUITING

Trial details

NCT number: NCT06682793
Sponsor: A2 Biotherapeutics Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult Colorectal Cancer Non-Small Cell Lung NSCLC (Non-small Cell Lung Cancer)Cancer Colon Cancer Rectal Cancer Lung Cancer CRC Head and Neck Squamous Cell Cancer HNSCC Renal Cell Carcinoma

Start date: 2025-05-22
Primary completion: 2029-03-31
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.